CHANGCHUN HIGH-TECH (000661.SZ) , China's leading innovation-driven pharma group, announced that it submitted today (29th) an application to the Hong Kong Stock Exchange for the issuance of H-shares and listing on the Main Board.

According to the preliminary prospectus, CHANGCHUN HIGH-TECH's sole sponsor is China Securities International. The net proceeds from the listing are intended to be used for clinical trials of the innovative pipeline, advancement of preclinical project development, and related regulatory affairs, among others.

In 1H25, CHANGCHUN HIGH-TECH's revenue dropped by 0.5% YoY to RMB6.603 billion, while its net profit sank by 42.8% to RMB980 million.
(A Shares quote is delayed for at least 15 mins.)